On November 17, 2023, Genentech, Inc., Hoffmann-La Roche Inc., and Biogen Inc. (“Plaintiffs”) filed a BPCIA complaint (“Complaint”) against Dr. Reddy’s Laboratories, Inc., Dr. Reddy’s Laboratories SA (“DRL SA”), Dr. Reddy’s Laboratories Ltd., Fresenius Kabi USA, LLC, Fresenius Kabi Swissbiosim Gmbh, and Fresenius Kabi Deutschland GmbH (“Defendants”) in the District of New Jersey, requesting the Court to block Defendants’ “DRL_RI,” a proposed biosimilar of Plaintiffs’ Rituxan® (rituximab), from entering the United States market.  Genentech, Inc. et al v. Dr. Reddy’s Laboratories, Inc. et al, D.N.J., No. 1:23-cv-22485.  Rituxan® is approved for various indications including for the treatment of adult patients with rheumatoid arthritis, non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis and microscopic polyangiitis.  In their complaint, Plaintiffs allege that Defendants infringe fifteen patents related to Rituxan®, including regarding its therapeutic uses, its administration, its formulation, and the processes by which it is manufactured.

An aBLA for DRL_RI was accepted by the FDA in July 2023 and is currently pending.  There are three other biosimilars of Rituxan® that have already been approved and launched: Truxima® (rituximab-abbs), Ruxience® (rituximab-pvvr), and Riabni™ (rituximab-arrx).  There have previously been several biosimilar litigations against the other biosimilars, all of which settled or were dismissed.  See, e.g.Biogen, Inc. et al v. Sandoz GmbH et al, D.N.J., No. 1:17-cv-13507; Biogen, Inc. et al v. Celltrion Healthcare Co., Ltd., D.N.J., No. 1:18-cv-00574; Biogen, Inc. et al v. Celltrion Healthcare Co., Ltd., D.N.J., No. 1:18-cv-11553; Sanofi-Aventis Deutschland GmbH, et al v. Biogen IDEC, Inc. et al, N.D. Cal., No. 3:08-cv-04909; Sanofi-Aventis Deutschland GmbH, et al v. Biogen IDEC, Inc. et al, N.D. Cal., No. 3:09-cv-04919; Celltrion Healthcare Co., et al v. Biogen, Inc. et al, N.D. Cal., No. 4:18-cv-00276.  

In the Genentech action, of the fifteen asserted patents, nine have not been previously asserted against other Rituxan® biosimilars.  The “patent dance” (42 U.S.C. § 262(1) outlines the framework) started on or about July 3, 2023 when the biosimilar (i.e., Defendant DRL SA) provided Plaintiffs with its aBLA for DRL_RI.  According to the Complaint, following receipt of the aBLA, Plaintiffs allege that the Defendants did not “meet its obligation to provide” other information that describes the “processes used to manufacture DRL_RI as required” by the BPCIA, and on August 1, 2023, requested Defendants provide the allegedly missing manufacturing information.  Despite the allegedly missing information, on September 1, 2023, Plaintiffs provided Defendants with a 3(A) list of fifteen patents that could reasonably be asserted against the DRL_RI product.  On November 16, 2023, Defendants provided the Plaintiffs a Notice of Commercial Marketing, starting a 180-day clock before the first possible date on which Defendants could market or sell DRL_RI.  Plaintiffs brought suit the day after receiving the Notice of Commercial Marketing on the fifteen patents on the 3(A) list “to preserve all rights.”  Plaintiffs are seeking, inter alia, a declaration of infringement and patent validity, damages and an injunction blocking sales of DRL_RI.

In 2022 Rituxan® had U.S. sales of almost $1.5B.

We continue to monitor this case.  For more information on this and other biosimilar litigations, visit



The authors would like to thank April Breyer Menon for her contributions to this article.


    Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website ( Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website ( Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.


    The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

    Subscribe for Future Updates